Literature DB >> 22246418

Managing cardiovascular risk in patients with chronic inflammatory diseases.

Boulos Haraoui1, Peter P Liu, Kim A Papp.   

Abstract

The role of traditional risk factors in the development of cardiovascular disease has been well studied. However, the relationship between chronic inflammatory conditions and cardiovascular risk has only recently been appreciated. Expression of numerous pro-inflammatory cytokines is common to the pathogenesis of both atherosclerosis and other chronic inflammatory diseases and may suggest that systemic inflammation independently contributes to elevated risk. This article examines the magnitude of cardiovascular risk in several of the most common chronic inflammatory diseases and summarizes currently available data to discern whether this risk is largely due to the presence of co-existing traditional risk factors for cardiovascular disease or the effect of increased systemic inflammation. Evidence is summarized to show which therapies may positively or negatively impact cardiovascular risk. Evidence is discussed in context of practical patient management tools, appropriate treatment based on risk, and treatment targets for high-risk patients. Overall, patients with chronic inflammatory diseases are at an often underestimated increase in cardiovascular risk and require individualized therapy and specific patient management strategies to address the disease process, cardiovascular risk factors, and comorbidities.

Entities:  

Mesh:

Year:  2012        PMID: 22246418     DOI: 10.1007/s10067-011-1921-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  49 in total

1.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

2.  Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

Authors:  Lennart T H Jacobsson; Carl Turesson; Anders Gülfe; Meliha C Kapetanovic; Ingemar F Petersson; Tore Saxne; Pierre Geborek
Journal:  J Rheumatol       Date:  2005-07       Impact factor: 4.666

3.  Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis.

Authors:  S Van Doornum; C Brand; B King; V Sundararajan
Journal:  Arthritis Rheum       Date:  2006-07

4.  Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.

Authors:  Joseph S Ross; David Madigan; Kevin P Hill; David S Egilman; Yongfei Wang; Harlan M Krumholz
Journal:  Arch Intern Med       Date:  2009-11-23

5.  Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.

Authors:  V F Panoulas; K M J Douglas; A Stavropoulos-Kalinoglou; G S Metsios; P Nightingale; M D Kita; M S Elisaf; G D Kitas
Journal:  Rheumatology (Oxford)       Date:  2008-01       Impact factor: 7.580

6.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

Review 7.  Reducing the cardiovascular disease burden in rheumatoid arthritis.

Authors:  Sharon Van Doornum; Garry L R Jennings; Ian P Wicks
Journal:  Med J Aust       Date:  2006-03-20       Impact factor: 7.738

8.  Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

Authors:  Joachim Listing; Anja Strangfeld; Jörn Kekow; Matthias Schneider; Andreas Kapelle; Siegfried Wassenberg; Angela Zink
Journal:  Arthritis Rheum       Date:  2008-03

9.  Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies.

Authors:  Rieke J B Driessen; Jan B Boezeman; Peter C M Van De Kerkhof; Elke M G J De Jong
Journal:  J Dermatolog Treat       Date:  2009       Impact factor: 3.359

10.  The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2008-09
View more
  6 in total

1.  Important issues at heart: cardiovascular risk management in rheumatoid arthritis.

Authors:  Camille Roubille; Boulos Haraoui
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

2.  Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis.

Authors:  Alexis Ogdie; Lihi Eder
Journal:  Int J Clin Rheumtol       Date:  2015-12

3.  Inflammation, telomere length, and grip strength: a 10-year longitudinal study.

Authors:  Daniel Baylis; Georgia Ntani; Mark H Edwards; Holly E Syddall; David B Bartlett; Elaine M Dennison; Carmen Martin-Ruiz; Thomas von Zglinicki; Diana Kuh; Janet M Lord; Avan Aihie Sayer; Cyrus Cooper
Journal:  Calcif Tissue Int       Date:  2014-05-25       Impact factor: 4.333

4.  Progression of carotid atherosclerosis in patients with systemic lupus erythematosus.

Authors:  Rosa W Telles; Cristina C D Lanna; Adriano J Sousa; Tulio P Navarro; Fabiana L Souza; Luciana A Rodrigues; Rodrigo C P Reis; Antonio L Ribeiro
Journal:  Clin Rheumatol       Date:  2013-04-26       Impact factor: 3.650

5.  Novel myokine: irisin may be an independent predictor for subclinic atherosclerosis in Behçet's disease.

Authors:  Abdullah Icli; Erkan Cure; Medine Cumhur Cure; Ali Ugur Uslu; Sevket Balta; Sevket Arslan; Davut Sakiz; Adem Kucuk
Journal:  J Investig Med       Date:  2016-03-03       Impact factor: 2.895

Review 6.  Nature-Based Interventions for Psychological Wellbeing in Long-Term Conditions: A Systematic Review.

Authors:  Eleanor M Taylor; Noelle Robertson; Courtney J Lightfoot; Alice C Smith; Ceri R Jones
Journal:  Int J Environ Res Public Health       Date:  2022-03-09       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.